Everything published about Tirzepatide: mechanism, research areas, results, regimens, risks, comparisons — plus the dated Vietnam price and ordering rules.
| Format | Price (index Nov 2, 2026) | Delivery |
|---|---|---|
| 20 mg | from 1 500 000 ₫ | Da Nang ~30 min · Vietnam 1–2 days |
Tirzepatide brings together two appetite and metabolic pathways: GIP and GLP-1. It helps explain why this peptide has become one of the most discussed names in weight-management research.
A dual GIP/GLP-1 receptor agonist. Licensed formulations are used for type 2 diabetes and chronic weight management in eligible populations.
A dual-action peptide with substantial clinical weight-management results and a clear connection to appetite and glucose regulation.
In a 72-week weight-management trial, adults without diabetes lost an average of 15.0%, 19.5% and 20.9% at 72 weeks in the 5, 10 and 15 mg groups, versus 3.1% with placebo. All groups received lifestyle support.
Licensed once-weekly subcutaneous schedule: Weeks 1–4: 2.5 mg weekly From week 5: 5 mg weekly Further increases: 2.5 mg at a time, after at least four weeks at the current dose. Weight-management maintenance doses: 5, 10 or 15 mg weekly; maximum 15 mg. Treatment is generally long term. A major weight-management trial followed participants for 72 weeks.
Nausea, diarrhoea, vomiting and constipation are common. Important precautions include pancreatitis, gallbladder disease, pregnancy, medullary thyroid cancer/MEN2 and hypoglycaemia with insulin or sulfonylureas. Oral contraceptives need an additional or non-oral method for four weeks after starting and each dose increase.
Tirzepatide activates GIP and GLP-1; semaglutide activates GLP-1. The additional GIP pathway is tirzepatide’s defining feature.
from 1 500 000 ₫ for 20 mg (index Nov 2, 2026); final total confirmed in writing before payment.
No: research material, not a prescription drug; no medical claims.